JP2019536767A - エピカテキン及び抗癌化合物の組合せを含む組成物 - Google Patents

エピカテキン及び抗癌化合物の組合せを含む組成物 Download PDF

Info

Publication number
JP2019536767A
JP2019536767A JP2019523821A JP2019523821A JP2019536767A JP 2019536767 A JP2019536767 A JP 2019536767A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019536767 A JP2019536767 A JP 2019536767A
Authority
JP
Japan
Prior art keywords
inhibitors
epicatechin
combination
cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019523821A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536767A5 (https=
Inventor
ドゥガー、サンディープ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sphaera Pharma Pvt Ltd
Original Assignee
Sphaera Pharma Pvt Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sphaera Pharma Pvt Ltd filed Critical Sphaera Pharma Pvt Ltd
Publication of JP2019536767A publication Critical patent/JP2019536767A/ja
Publication of JP2019536767A5 publication Critical patent/JP2019536767A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
    • C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2019523821A 2016-11-01 2017-11-01 エピカテキン及び抗癌化合物の組合せを含む組成物 Pending JP2019536767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201611037375 2016-11-01
IN201611037375 2016-11-01
PCT/IN2017/050506 WO2018083713A1 (en) 2016-11-01 2017-11-01 Composition comprising combination of epicatechin and anti-cancer compound

Publications (2)

Publication Number Publication Date
JP2019536767A true JP2019536767A (ja) 2019-12-19
JP2019536767A5 JP2019536767A5 (https=) 2020-12-03

Family

ID=62076542

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019523821A Pending JP2019536767A (ja) 2016-11-01 2017-11-01 エピカテキン及び抗癌化合物の組合せを含む組成物

Country Status (5)

Country Link
US (1) US20190262347A1 (https=)
EP (1) EP3535252A4 (https=)
JP (1) JP2019536767A (https=)
CN (1) CN110312709A (https=)
WO (1) WO2018083713A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162126A1 (ja) * 2020-02-13 2021-08-19 シーシーアイホールディングス株式会社 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および／または予防用医薬組成物

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012170430A1 (en) 2011-06-06 2012-12-13 Cardero Therapeutics, Inc. Methods and compositions for treatment of mitochondrial toxicity
US20180193306A1 (en) 2012-03-23 2018-07-12 Cardero Therapeutics, Inc. Compounds and compositions for the treatment of muscular disorders and bone disorders
CN106714770B (zh) 2014-07-23 2024-04-19 斯法尔制药私人有限公司 羟基类固醇化合物、其中间体、制备方法、组合物及其用途
EP3472176B1 (en) 2016-06-21 2024-05-15 Sphaera Pharma Pvt. Ltd. Utility of (+) epicatechin and their analogs
BR112021007684A2 (pt) 2018-10-24 2021-07-27 Epirium Bio Inc. cocristal, composição farmacêutica, métodos para tratar uma doença ou distúrbio que se beneficiaria da modificação da cadeia de transporte de elétrons, para reduzir os níveis de triglicerídeos, para tratar uma doença ou distúrbio selecionado a partir do grupo que consiste em uma síndrome metabólica, diabetes tipo ii, uma hiperlipidemia congênita e hiperlipidemia induzida por drogas, para tratar uma condição relacionada à disfunção mitocondrial, para melhorar o desempenho esportivo, resistência, construção de forma ou força muscular, ou facilitar a recuperação dos efeitos do treinamento ou competição e para tratar ou prevenir distrofinopatia, sarcoglicanopatia ou disferlinopatia, processo para preparar um cocristal, e, uso de um cocristal
CN115025236B (zh) * 2022-05-09 2024-03-08 聊城大学 一种加载化疗药物-茶多酚联合药物的pH响应型靶向DNA纳米载药体系
WO2024036225A1 (en) 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin for inhibiting glutamate toxicity
WO2024036223A1 (en) 2022-08-10 2024-02-15 Epirium Bio Inc. Epicatechin inhibiting atp hydrolysis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
JP2011105763A (ja) * 2000-06-21 2011-06-02 Kao Corp Ｐｐａｒ依存的遺伝子転写活性化剤
JP2015526424A (ja) * 2012-07-23 2015-09-10 スファエラ ファーマ ピーティーイー リミテッド 新規トリアジン化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192612B2 (en) * 2001-02-22 2007-03-20 Purdue Research Foundation Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011105763A (ja) * 2000-06-21 2011-06-02 Kao Corp Ｐｐａｒ依存的遺伝子転写活性化剤
US20070054868A1 (en) * 2005-06-20 2007-03-08 The Trustees Of Columbia University In The City Of New York Synergistic polyphenol compounds, compositions thereof, and uses thereof
JP2015526424A (ja) * 2012-07-23 2015-09-10 スファエラ ファーマ ピーティーイー リミテッド 新規トリアジン化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AM.J.PHYSIOL.RENAL PHYSIOL., vol. 303, JPN6021030799, 2012, pages 1264 - 1274, ISSN: 0004567188 *
ANTICANCER RESEARCH, vol. 32, JPN6021030797, 2012, pages 2905 - 2913, ISSN: 0004721795 *
PLOS ONE, vol. 9, JPN6021030798, 2014, pages 88322, ISSN: 0004721796 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021162126A1 (ja) * 2020-02-13 2021-08-19 シーシーアイホールディングス株式会社 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および／または予防用医薬組成物

Also Published As

Publication number Publication date
WO2018083713A1 (en) 2018-05-11
US20190262347A1 (en) 2019-08-29
EP3535252A1 (en) 2019-09-11
CN110312709A (zh) 2019-10-08
EP3535252A4 (en) 2020-06-17

Similar Documents

Publication Publication Date Title
JP2019536767A (ja) エピカテキン及び抗癌化合物の組合せを含む組成物
Chen et al. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer
JP5785157B2 (ja) Ｐｌｋ１阻害剤および抗腫瘍剤を含む治療組合せ
Bayati et al. Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells
Winegarden et al. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer
CN111902147A (zh) 五氮杂大环状环配合物和基于铂的抗癌剂的组合癌症治疗
Park et al. Effects of combination therapy of docetaxel with selenium on the human breast cancer cell lines MDA-MB-231 and MCF-7
Ahn et al. 5-Nitro-5′-hydroxy-indirubin-3′-oxime (AGM130), an indirubin-3′-oxime derivative, inhibits tumor growth by inducing apoptosis against non-small cell lung cancer in vitro and in vivo
Folkvord et al. Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
KR20190056758A (ko) 종양줄기세포 특성의 암을 치료하기 위한 항암 병용 요법
US20250387406A1 (en) Therapy for reduced ototoxicity from chemotherapeutic agent with pentaaza macrocyclic ring complex
JP5694782B2 (ja) 肺癌、腺癌及び他の病状のための治療方法及び組成物
EP2996773A2 (en) Administration of nedd8-activating enzyme inhibitor and chemotherapeutic agents
JP2020512408A (ja) 肺がんの治療に使用するための組み合わせ
CA3135916C (en) COMBINED USE OF THE COMPOUND MEDICINE A-NOR-5A ANDROSTANE AND AN ANTI-CANCER MEDICINE
AU2013233094A1 (en) Novel antitumor agent comprising combination of three agents
CA2831208A1 (en) Method of treating prostate cancer
TW201800091A (zh) 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物
RS62560B1 (sr) Antitumorski lek koji sadrži antitumorski kompleks platine, i pojačivač antitumorskog efekta
JP2023536389A (ja) ペンタアザ大環状環複合体およびホルモン療法剤の併用がん治療法
EP4157242A1 (en) Combination cancer therapy with pentaaza macrocyclic ring complex and hormone therapy agent
WO2016046316A1 (en) Antitumor activity of multi-kinase inhibitors in colorectal cancer
Seminara et al. Mitomycin C and Etoposide in Advanced Colorectal Carcinoma: A Clinical and in vitro Experience That Focuses the Problem of Schedule Dependence in Combination Therapy
Seifart et al. Randomised phase II study comparing topotecan/carboplatin administration for 5 versus 3 days in the treatment of extensive-stage small-cell lung cancer
Scheulen et al. 496 A phase I dose-escalation study of BI 811283, an Aurora B inhibitor, administered day 1 and 15 every four weeks, in patients with advanced solid tumours

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201021

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210730

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210810

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220308